Hospital
Faith Regional Health Services
Faith Regional Health Services was paid $7.30M by Medicaid between Jan 2018 and Dec 2024, across 165 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoFAITH REGIONAL HEALTH SERVICES
NORFOLK, NE 68701
NORFOLK, NE 68701
33aNPI1285676544assigned 06/12/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$7.30M
24GClaims208,777
24DCodes billed165
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Nebraska
Rank by total paid#2 of 5
Median peer was paid$1.33M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,477 | $837K | |
| 2019 | 28,718 | $828K | |
| 2020 | 24,740 | $953K | |
| 2021 | 47,443 | $1.50M | |
| 2022 | 47,824 | $1.69M | |
| 2023 | 22,527 | $959K | |
| 2024incomplete | 9,048 | $539K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 7,572 | 6,969 | $1.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 6,203 | 5,795 | $869K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.1% | 5,449 | 5,098 | $590K |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.9% | 2,022 | 1,758 | $576K |
| G0378 | Hospital observation service, per hour | 7.1% | 1,910 | 1,601 | $521K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.7% | 6,895 | 1,825 | $491K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.2% | 1,672 | 841 | $383K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.8% | 1,964 | 874 | $353K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 889 | 824 | $326K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 1,188 | 1,096 | $260K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 2,265 | 2,041 | $253K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.7% | 676 | 651 | $199K |
153 more codes
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,074 | $80K |
| 80053 | Comprehensive metabolic panel | 1.0% | 14,176 | $74K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 986 | $66K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,820 | $66K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 316 | $58K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,276 | $55K |
| 87631 | <1% | 360 | $54K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 918 | $50K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,899 | $39K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 407 | $37K |
| J3490 | Unclassified drugs | <1% | 13,281 | $36K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 272 | $33K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 92 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,440 | $32K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 643 | $29K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,991 | $28K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 726 | $27K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,955 | $24K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,525 | $23K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,600 | $23K |
| 80050 | General health panel | <1% | 999 | $21K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 655 | $21K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,231 | $21K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 165 | $19K |
| 80061 | Lipid panel | <1% | 3,070 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,778 | $16K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,438 | $16K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 587 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 724 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,538 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,477 | $15K |
| 84439 | <1% | 1,837 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,947 | $15K |
| 86850 | <1% | 962 | $12K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 132 | $10K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 38 | $9K |
| 36591 | <1% | 314 | $9K | |
| 97165 | <1% | 84 | $8K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 15 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 305 | $8K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 7,057 | $7K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 27 | $7K |
| 87070 | <1% | 1,136 | $7K | |
| 87806 | <1% | 272 | $7K | |
| 87077 | <1% | 1,732 | $7K | |
| 97161 | <1% | 180 | $6K | |
| 86900 | <1% | 1,053 | $6K | |
| 93971 | <1% | 63 | $6K | |
| 81001 | <1% | 3,378 | $6K | |
| 43249 | <1% | 18 | $6K | |
| 82728 | <1% | 493 | $5K | |
| 87186 | <1% | 1,441 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,878 | $5K |
| 83690 | <1% | 1,791 | $4K | |
| 86140 | <1% | 806 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 122 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,146 | $4K |
| 84484 | <1% | 2,306 | $4K | |
| 93970 | <1% | 31 | $4K | |
| 84703 | <1% | 1,103 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,875 | $4K |
| 80047 | <1% | 348 | $3K | |
| 94060 | <1% | 44 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 86 | $3K |
| 83735 | <1% | 1,307 | $3K | |
| 83550 | <1% | 479 | $3K | |
| 85610 | <1% | 2,139 | $3K | |
| 0099U | <1% | 15 | $3K | |
| 83540 | <1% | 560 | $3K | |
| 82962 | <1% | 1,831 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 73 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $2K |
| 86901 | <1% | 1,091 | $2K | |
| 82570 | <1% | 621 | $2K | |
| A9270 | Non-covered item or service | <1% | 2,866 | $2K |
| 80306 | <1% | 389 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 24 | $2K |
| 81003 | <1% | 1,679 | $2K | |
| 87040 | <1% | 497 | $2K | |
| 94726 | <1% | 28 | $2K | |
| 87506 | <1% | 13 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,123 | $2K |
| 86592 | <1% | 196 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 24 | $2K |
| 85730 | <1% | 1,024 | $2K | |
| 80076 | <1% | 282 | $2K | |
| 82607 | <1% | 118 | $1K | |
| 85652 | <1% | 576 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 215 | $1K |
| 83880 | <1% | 140 | $1K | |
| 71250 | <1% | 16 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 409 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,101 | $1K |
| 93017 | <1% | 12 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 16 | $1K |
| 94729 | <1% | 28 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,027 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 493 | $952.22 |
| 84145 | <1% | 303 | $907.04 | |
| 72100 | <1% | 31 | $865.73 | |
| 43251 | <1% | 26 | $862.06 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,351 | $708.96 |
| 87075 | <1% | 203 | $690.58 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 43 | $665.43 |
| 74019 | <1% | 13 | $653.02 | |
| 87653 | <1% | 13 | $627.13 | |
| 87205 | <1% | 287 | $574.74 | |
| 83605 | <1% | 288 | $511.23 | |
| 86787 | <1% | 36 | $437.09 | |
| 97116 | <1% | 25 | $432.56 | |
| 80164 | <1% | 47 | $376.23 | |
| 85379 | <1% | 285 | $324.53 | |
| 87188 | <1% | 252 | $324.36 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15 | $321.90 |
| 85004 | <1% | 79 | $276.37 | |
| 82043 | <1% | 104 | $259.68 | |
| 87340 | <1% | 43 | $253.73 | |
| 97162 | <1% | 14 | $250.10 | |
| 85027 | <1% | 79 | $239.46 | |
| 84100 | <1% | 218 | $187.23 | |
| 82947 | <1% | 29 | $169.89 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 149 | $161.16 |
| 86762 | <1% | 15 | $142.02 | |
| 84156 | <1% | 41 | $141.59 | |
| 36416 | <1% | 112 | $131.76 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 1,036 | $104.08 |
| 81025 | <1% | 97 | $99.52 | |
| 87147 | <1% | 14 | $71.94 | |
| 84481 | <1% | 12 | $68.76 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 544 | $62.34 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 169 | $56.61 |
| 82272 | <1% | 12 | $38.07 | |
| 99152 | <1% | 16 | $21.54 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 391 | $13.72 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 77 | $13.64 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 50 | $8.61 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,005 | $4.40 |
| C1769 | Guide wire | 0% | 14 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 18 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 15 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 19 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 71 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 14 | $0.00 |
| 80320 | 0% | 16 | $0.00 | |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 13 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 169 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 38 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 186 | $0.00 |
| 76942 | 0% | 40 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 18 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 29 | $0.00 |
| 87641 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDRISCOLL, KELLY (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Faith Regional Health Services | Norfolk, NE | $698K |
| Northeast Nebraska Surgery Center LLC | Norfolk, NE | $148K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.